Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Editas Medicine, Inc.

NASDAQ: EDIT · Life Sciences · 5 alerts · CIK 1650664

Share price
$1.87Close, Nov 16
Market cap
$289M
Shares outstanding
154.34MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Editas Medicine, Inc. filings on SEC EDGAR ↗

7:05 AM ET 8-K
Business Update

Editas Medicine Business Update

Editas Medicine received approval to initiate its Phase 1/2 Strive clinical trial for EDIT-401 in Australia, targeting patients with heterozygous familial hypercholesterolemia. The company expects to begin patient dosing in 2026 and report initial safety and tolerability data in the first quarter of 2027. Additionally, the company will present new preclinical data demonstrating durable LDL-C reduction at the AHA Scientific Sessions in November 2026.

Counterparty
Therapeutic Goods Administration

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.